Retail speculation on imminent REGAL AML readout sparks SLS surge
Retail speculation on imminent REGAL AML readout sparks 14% SLS surge
- As of May 2026, REGAL Phase 3 trial for GPS in AML had reached 78 of 80 events needed for topline OS data; July speculation centers on the 80th event triggering analysis.
- CEO Angelos Stergiou scheduled for Fox & Friends appearance next week to discuss "novel clinical developments," echoing prior patterns before data releases (per retail chatter).
- Stock rebounded sharply from July 16 close at $11.75 (down ~8%); intraday gains hit 10-14% toward $13 amid heavy buying volume.
- Ongoing retail buzz on Stocktwits/Reddit highlights buyout potential, options activity, short squeeze signals, and recent Seeking Alpha article hyping imminent catalyst.
- Company maintains strong cash position (> $100M post-Q1/warrants) with no recent PR; hype builds on June severance updates and analyst targets up to $25-27.50.
- No official trial update or PR today; movement tied to anticipation rather than new verifiable data per available reports.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.